Mifepristone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Mifepristone
- Mifepristone: Original Indication Not Specified — Predicted New Use: Punctate Epithelial Keratoconjunctivitis
Mifepristone: Original Indication Not Specified — Predicted New Use: Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Mifepristone (DrugBank DB00834) is a well-established prescription medicine, but this evidence pack does not contain its original approved indication or mechanism-of-action data. The TxGNN model predicts a possible new use for Punctate Epithelial Keratoconjunctivitis, but this prediction is currently supported by no clinical trials and no published literature — it is a computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack |
| Predicted New Indication | Punctate epithelial keratoconjunctivitis |
| TxGNN Prediction Score | 97.60% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for mifepristone in this evidence pack. Elsewhere in the evidence pack, mifepristone is described as a progesterone/glucocorticoid receptor antagonist, which is consistent with its widely recognised pharmacological class — but no source-verified original indication or MOA record was provided here, so this cannot be confirmed against a primary reference in this report.
There is no identified mechanistic or pathophysiological link between mifepristone’s known pharmacology (progesterone/glucocorticoid receptor antagonism) and punctate epithelial keratoconjunctivitis, which is primarily an infectious/inflammatory ocular surface condition. The evidence pack itself states this explicitly: the TxGNN score reflects graph-embedding similarity only, with no known pharmacological rationale connecting the two.
Given the complete absence of supporting mechanism, trial, or literature evidence, this prediction should be treated as an early-stage hypothesis generated purely by the model, not as a clinically or mechanistically grounded signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Mifepristone is not currently registered on the ARTG (Australian Register of Therapeutic Goods) according to this evidence pack — 0 entries found.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (punctate epithelial keratoconjunctivitis) has no supporting clinical trials, no literature, and no mechanistic rationale — this is an L5, model-prediction-only signal. In addition, mifepristone is not currently marketed in Australia and this evidence pack lacks even basic drug-level data (original indication, MOA, TGA/PI warnings), so no safety or applicability assessment can be made at this time.
To proceed, the following is needed:
- Original approved indication and mechanism-of-action data for mifepristone (currently a Blocking/High-severity data gap in this pack)
- TGA-approved Product Information, including warnings, contraindications and drug interactions
- Any preclinical or mechanistic studies specifically linking mifepristone to ocular surface/keratoconjunctivitis pathology, if this candidate is to be pursued further
- Consideration of the other predicted candidates in this evidence pack (e.g. rosacea, post-infectious syndrome) that carry at least L4-level mechanistic or trial-adjacent evidence, which may warrant evaluation ahead of this top-ranked but evidence-free candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.